山东医药
山東醫藥
산동의약
Shandong Medical Journal
2015年
38期
21-23
,共3页
李倩%任琛琛%杨立%薛景戈%白杨%张娟%黄玲
李倩%任琛琛%楊立%薛景戈%白楊%張娟%黃玲
리천%임침침%양립%설경과%백양%장연%황령
上皮性卵巢癌%叉头框转录因子%FOXC1基因%DNA甲基化%基因表达
上皮性卵巢癌%扠頭框轉錄因子%FOXC1基因%DNA甲基化%基因錶達
상피성란소암%차두광전록인자%FOXC1기인%DNA갑기화%기인표체
ovarian tumor%forkhead box%FOXC1 gene%methylation%gene expression
目的:观察卵巢上皮性肿瘤中FOXC1 mRNA表达变化及其启动子区甲基化情况。方法选择30例上皮性卵巢癌(A组)、14例交界性卵巢上皮性肿瘤(B组)和21例良性卵巢上皮性肿瘤患者(C组),取其手术切除卵巢组织标本,用RT-PCR法检测FOXC1 mRNA,用甲基化特异聚合酶链反应方法( MSP )结合琼脂糖凝胶电泳检测FOXC1基因启动子区甲基化状态及频率。结果 A、B、C组FOXC1 mRNA相对表达量分别为0.38±0.16、0.61±0.18、1.19±0.17,A组低于B组,B组低于C组(P均<0.05)。 A组卵巢癌组织中FOXC1 mRNA相对表达量与临床分期及分化程度无关,与淋巴结转移有关( P<0.05)。 A、B、C组卵巢组织中FOXC1基因启动子区甲基化频率分别为66.7%、50.0%、9.5%,A组高于B组,B组高于C组(P均<0.05)。 A组FOXC1基因启动子区甲基化、未甲基化者FOXC1 mRNA相对表达量分别为0.32±0.14、0.45±0.17,P<0.05。结论上皮性卵巢癌组织中FOXC1 mRNA表达下降,FOXC1 mRNA表达与上皮性卵巢癌淋巴结转移有关。 FOXC启动子区甲基化状态与其mRNA表达抑制相关。
目的:觀察卵巢上皮性腫瘤中FOXC1 mRNA錶達變化及其啟動子區甲基化情況。方法選擇30例上皮性卵巢癌(A組)、14例交界性卵巢上皮性腫瘤(B組)和21例良性卵巢上皮性腫瘤患者(C組),取其手術切除卵巢組織標本,用RT-PCR法檢測FOXC1 mRNA,用甲基化特異聚閤酶鏈反應方法( MSP )結閤瓊脂糖凝膠電泳檢測FOXC1基因啟動子區甲基化狀態及頻率。結果 A、B、C組FOXC1 mRNA相對錶達量分彆為0.38±0.16、0.61±0.18、1.19±0.17,A組低于B組,B組低于C組(P均<0.05)。 A組卵巢癌組織中FOXC1 mRNA相對錶達量與臨床分期及分化程度無關,與淋巴結轉移有關( P<0.05)。 A、B、C組卵巢組織中FOXC1基因啟動子區甲基化頻率分彆為66.7%、50.0%、9.5%,A組高于B組,B組高于C組(P均<0.05)。 A組FOXC1基因啟動子區甲基化、未甲基化者FOXC1 mRNA相對錶達量分彆為0.32±0.14、0.45±0.17,P<0.05。結論上皮性卵巢癌組織中FOXC1 mRNA錶達下降,FOXC1 mRNA錶達與上皮性卵巢癌淋巴結轉移有關。 FOXC啟動子區甲基化狀態與其mRNA錶達抑製相關。
목적:관찰란소상피성종류중FOXC1 mRNA표체변화급기계동자구갑기화정황。방법선택30례상피성란소암(A조)、14례교계성란소상피성종류(B조)화21례량성란소상피성종류환자(C조),취기수술절제란소조직표본,용RT-PCR법검측FOXC1 mRNA,용갑기화특이취합매련반응방법( MSP )결합경지당응효전영검측FOXC1기인계동자구갑기화상태급빈솔。결과 A、B、C조FOXC1 mRNA상대표체량분별위0.38±0.16、0.61±0.18、1.19±0.17,A조저우B조,B조저우C조(P균<0.05)。 A조란소암조직중FOXC1 mRNA상대표체량여림상분기급분화정도무관,여림파결전이유관( P<0.05)。 A、B、C조란소조직중FOXC1기인계동자구갑기화빈솔분별위66.7%、50.0%、9.5%,A조고우B조,B조고우C조(P균<0.05)。 A조FOXC1기인계동자구갑기화、미갑기화자FOXC1 mRNA상대표체량분별위0.32±0.14、0.45±0.17,P<0.05。결론상피성란소암조직중FOXC1 mRNA표체하강,FOXC1 mRNA표체여상피성란소암림파결전이유관。 FOXC계동자구갑기화상태여기mRNA표체억제상관。
Objective To study the correlation among transcriptional expression and promoter methylation of FOXC 1 gene in epithelial ovarian tumors and its clinical characteristics .Methods Methylation-specific PCR was used to detect the methylation of FOXC1 gene promoter CpG island in 65 patients who underwent operation for epithelial ovarian tumors ,re-verse transcription PCR was performed to detect the expression of FOXC 1 mRNA.Result FOXC1 mRNA was showed in all epithelial ovarian tumor samples .The relative level of FOXC1 mRNA was 1.19 ±0.17 in benign tumors, 0.61 ±0.18 in borderline tumors and 0.38 ±0.16 in malignant tumors respectively .It was significantly lower in ovarian cancer than that in benign tumor specimens , and was significantly lower in borderline tumor than that in benign tumor too (P<0.05).The expression of FOXC1 was not correlated with clinical characteristics , such as clinical stage , histological differentiation . However there were lower expression level of FOXC 1 mRNA in patients with lymph node metastasis than that of patients without lymph node metastasis .The methylation rate of the FOXC1 gene promoter CpG island in ovarian cancer was higher than those in borderline tumor and the benign tumor ,P<0.05.Conclution The expression of FOXC1 is closely correlated with the oncogenesis and progress of ovarian cancer .Promoter methylation may contribute to the low level of mRNA expres-sion.